Pexastimogene devacirepvec
Pexastimogene devacirepvec is a gene pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 3 | 2 | — | — | — | 4 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 3 | — | — | — | 4 |
| Renal cell carcinoma | D002292 | 2 | 1 | — | — | — | 2 | ||
| Melanoma | D008545 | 2 | 1 | — | — | — | 2 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
| Neoplasms | D009369 | C80 | 1 | 1 | — | — | — | 1 | |
| Sarcoma | D012509 | 1 | 1 | — | — | — | 1 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | C34.90 | 1 | — | — | — | — | 1 | |
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | — | 1 | ||
| Lymphoma | D008223 | C85.9 | 1 | — | — | — | — | 1 | |
| Neuroblastoma | D009447 | EFO_0000621 | 1 | — | — | — | — | 1 | |
| Ewing sarcoma | D012512 | EFO_0000173 | 1 | — | — | — | — | 1 | |
| Rhabdomyosarcoma | D012208 | 1 | — | — | — | — | 1 | ||
| Wilms tumor | D009396 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PEXASTIMOGENE DEVACIREPVEC |
| INN | pexastimogene devacirepvec |
| Description | JX-594 is an oncolytic virus is designed to target and destroy cancer cells. It is also known as Pexa-Vec, INN pexastimogene devacirepvec) and was constructed in Dr. Edmund Lattime's lab at Thomas Jefferson University, tested in clinical trials on melanoma patients, and licensed and further developed by SillaJen.
|
| Classification | Gene |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3039547 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | K82DG47I0G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 29 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more